Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Vaccinations01:51

Vaccinations

Overview
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same author

Vitamin A and body weight status do not impact humoral immunity against measles, mumps or rubella in individuals 4 to 18 years old: a cross-sectional cohort study in India.

Vaccine·2026
Same author

Cytomegalovirus serostatus and plasma MCP-1 levels are associated with antibody response to seasonal influenza vaccine across age and sex.

medRxiv : the preprint server for health sciences·2026
Same author

Sex-based differences in mumps immunity after a third dose of measles-mumps-rubella vaccine.

Vaccine·2026
Same author

Seroprevalence of mumps and rubella antibodies among Indian children: evidence of a mumps immunity gap.

Vaccine·2026
Same author

COVID-19 vaccine policy: a response and way forward.

Vaccine·2026

Related Experiment Video

Updated: Jul 6, 2026

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

Emerging vaccines for influenza.

Pritish K Tosh1, Gregory A Poland

  • 1Mayo Clinic Vaccine Research Group, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

Expert Opinion on Emerging Drugs
|March 7, 2008
PubMed
Summary

New influenza vaccine technologies like DNA vaccines show promise for better protection, especially for at-risk groups. Global research accelerates to combat seasonal flu and potential pandemics.

Area of Science:

  • Immunology
  • Vaccinology
  • Infectious Diseases

Background:

  • Influenza causes significant global morbidity and mortality.
  • Current vaccines are less effective in high-risk populations (children, elderly, immunocompromised).
  • Emerging strains like avian influenza pose pandemic threats.

Purpose of the Study:

  • To review global research on novel influenza vaccines, adjuvants, and delivery systems.
  • To highlight advancements in vaccine technology for improved influenza prevention.

Main Methods:

  • Literature search of MEDLINE and Pharmaprojects databases.
  • Analysis of ongoing research in influenza vaccine technologies.

Main Results:

  • DNA vaccines, live recombinant viral vector vaccines, and virus-like particles demonstrate strong immunogenicity.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

Related Experiment Videos

Last Updated: Jul 6, 2026

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies
07:55

Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies

Published on: August 29, 2017

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

  • These novel platforms offer protection against experimental influenza challenge.
  • New vaccine delivery methods and rapid production techniques are under development.

    • Conclusions:

    • Advanced vaccine technologies hold significant promise for enhanced influenza immunity.
    • Global research efforts are actively addressing the need for improved vaccines against seasonal and pandemic influenza.
    • Continued innovation is crucial for public health preparedness.